Regeneus Ltd

If you missed the $RGS investor session this week, you can catch up below to hear CEO @rosickas provide an update on the Company’s partnerships with @KYOCERA_Global and @DeptDefence for Progenza™ and Sygenus. #regenmed #CEOtalks #investors youtu.be/4CMgWsmFT90

During her studies, Dr. Zheng collaborated closely with industry partner @Regeneus and received guidance from her co-supervisors: Associate Professor Tracy Heng, Professor Laurence Meagher from Monash University, and Professor Graham Vesey from Regeneus.

Regeneus team at #BIO2023. Contact us for partnering opportunities!

Our AGM is starting in 2 hours (11am Sydney time)! Join us at Dentons Australia, Level 16, 77 Castlereagh Street, Sydney. Prior registration is not required.

Join us tomorrow for our AGM! Time: 11am (Sydney time), Tuesday the 29th November Location: Dentons Australia, Level 16, 77 Castlereagh Street, Sydney Prior registration is not required.

Check out our latest corporate presentation! Regeneus are progressing Progenza for knee osteoarthritis in Japan and the USA, and Sygenus for pain in Australia: regeneus.com.au/wp-content/upl… #regenerativemedicine #stemcelltherapy #regenmed #osteoarthritis #pain

Regeneus are attending the Alliance for Regenerative Medicine Cell and Gene Meeting on the Mesa in California (11-13th October 2022). Reach out and connect with Regeneus' CEO Karolis Rosickas! lnkd.in/eiUpMy4 #cgmesa22 #regenmed #stemcelltherapy

Regeneus scientists characterise Progenza™ Medicinal Signaling Cells using flow cytometry. Learn more about the science behind Regeneus: buff.ly/3fD9L4r #regenmed

Pictured: Regeneus R&D Scientist Brian Saputro performing quality control on Progenza™ by taking samples for cytokine profile analysis. Learn more about the science behind Regeneus: buff.ly/3fD9L4r #regenmed

From the team here at Regeneus, we wish you a very happy, safe and well-deserved break this holiday season. To our investors, thank you for your continued support. We look forward to sharing more positive updates in the New Year. #happyholidays #regenmed $RGS

There is a strong focus on Australia's regenerative medicine future in the latest edition of @AusBiotech's Journal. Read pages 60-62 to see why we are so excited to be part of the sector that's developing groundbreaking therapies for patients. #regenmed #industrytrends $RGS

Regeneus R&D Manager Flyn McKinnirey has an unwavering commitment to investigating new and innovative ways to enhance our products and deliver the best possible patient outcome. Learn more about Flyn's role at Regeneus: buff.ly/3pRJAM1 #regenmed $RGS

Behind the scenes at Regeneus, our scientists perform regular cell counts on our lead technology platform Progenza™ to ensure the quality of the product. Read more about Progenza™: buff.ly/3lLWqtY #regenmed

Published in Nature, $RGS R&D Manager Flyn McKinnirey’s paper: ‘Immune modulation via adipose derived Mesenchymal Stem cells is driven by donor sex in vitro’ uncovers the difference in potency and functionality between female and male adipose derived MSCs. buff.ly/3EvwhXL

Pictured: $RGS Research Scientist Chrys Maoudis conducting an immunoassay, testing for batch to batch consistency of the Medicinal Signaling Cell secretome used in Progenza™ and Sygenus. Read about the science behind Regeneus: regeneus.com.au/science/ #regenmed #behindthescenes

$RGS is on track to fulfil its obligations and earn future milestone payments and royalties under our agreement with @kyocera_global in Japan. Hear more from Regeneus CEO @rosickas on the Company's strategy for Progenza™ in Japan: youtu.be/BmzJ56QN0wk

Australia's #regenmed landscape is rapidly evolving with the opportunity to become a global sector leader. In fact, @AusBiotech suggests the success of Australia's regenerative medicine sector could be worth at least $6 billion in annual revenue. Read: bit.ly/3kDm9V0

Meet Dr. Cindy Shu who joins $RGS from @Sydney_Uni's @KollingINST as part of the @MTPConnect_AUS #REDI Fellowship Grant. Dr. Shu's expertise in OA pathophysiology, animal models & immune cell analysis will support the Progenza™ clinical program. #regenmed bit.ly/30ctsfy

Last chance to register! $RGS CEO Karolis Rosickas is hosting a webinar tomorrow, 4 November at 2pm AEDT to update investors on the Company's technology. Register here: us02web.zoom.us/webinar/regist… #regenmed #webinar

Regeneus' CEO Karolis Rosickas will be hosting an investor webinar on the 4th November at 2pm AEDT covering RGS' progress with its Progenza technology and ongoing partnerships. Join here: us02web.zoom.us/webinar/regist…